Product Information
VIMPAT 50 MG TABLET is a brand product labeled by UCB, Inc., priced at $11.8292 per EA under NDC 00131247760. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Oct 28, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lacosamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/1
Manufacturer
UCB, Inc.NDC
00131247760
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LACOSAMIDEApproval Type
New Drug (NDA)
FDA Application
NDA022253FDA Approved
10/28/2008
TE Code
AB
On Market Since
5/26/2009
Pharmacological Classes
Price Statistics
The NADAC for VIMPAT 50 MG TABLET has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 115.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.8292 per EA |
|---|---|
| All-time high | $11.8546 (May 13, 2026) |
| All-time low | $5.4781 (Nov 28, 2013) |
| 52-week high | $11.8546 |
| 52-week low | $11.5467 |
| Median price | $9.1097 |
| Average price | $9.0206 |
| Largest weekly change | +9.9% (Jan 8, 2014) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VIMPAT 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VIMPAT 50 MG TABLET, manufactured by UCB, Inc., is $11.8292 per EA (NDC 00131247760), effective Aug 19, 2026.
How has the price of VIMPAT 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for VIMPAT 50 MG TABLET has risen 115.9%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VIMPAT 50 MG TABLET?
Since Nov 28, 2013, the NADAC for VIMPAT 50 MG TABLET has ranged from a low of $5.4781 (Nov 28, 2013) to a high of $11.8546 (May 13, 2026), with a median of $9.1097 per EA.
Are there cheaper alternatives to VIMPAT 50 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LACOSAMIDE 50 MG TABLET, is $0.1153 per EA — about 99% below VIMPAT 50 MG TABLET.
Who manufactures VIMPAT 50 MG TABLET?
VIMPAT 50 MG TABLET (NDC 00131247760) is labeled by UCB, Inc., and CMS classifies it as a brand product.